Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia^[1]. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion^[2]. IC50 & Target: Thrombin^[1]